Sai Parenterals' Rs 409 crore IPO is set for a flat debut with a 0% grey market premium, reflecting subdued investor sentiment and weak retail subscription. Despite a diversified pharma business and expansion plans, aggressive valuations at over 70 times P/E appear to have deterred individual investors, though institutional participation helped the issue scrape through.

Sai Parenterals shares to debut today. Check GMP ahead of listing

Sai Parenterals' Rs 409 crore IPO is headed for a muted stock market debut, with the grey market premium (GMP) at 0%, indicating expectations of a flat listing when shares hit the bourses on April 2. The lack of any premium in the unofficial market reflects subdued investor sentiment, particularly after weak subscription trends and broader caution in primary markets.

The IPO, priced in the range of Rs 372-392 per share, saw an overall subscription of just 1.08 times, suggesting limited enthusiasm despite a diversified pharmaceutical business and expansion-led growth plans.

Retail interest collapses

The biggest drag on the issue came from retail investors, where the IPO was subscribed a mere 0.12 times, one of the weakest responses seen in recent offerings. This sharp undersubscription in the retail segment signals a clear shift in investor behaviour, with individuals turning cautious after a phase of inconsistent listing gains and negative post-listing returns across several IPOs.

In contrast, institutional participation remained relatively stable. Qualified institutional buyers subscribed their portion 1.73 times, while non-institutional investors (NIIs) bid 2.45 times, helping the issue scrape through full subscription.

Live Events

Valuations dent sentiment

Sai Parenterals, while operating in a stable pharmaceutical segment, appears to have been priced aggressively. At the upper band, the company commands a P/E of over 70 times, which may have deterred retail participation, according to analysts.

Business fundamentals intact, but valuation a concern

The company operates across branded generics and contract development and manufacturing (CDMO), with a diversified portfolio spanning cardiovascular, anti-diabetic, respiratory and other therapeutic segments.

It has also expanded into exports after acquiring internationally accredited facilities, targeting regulated and semi-regulated markets such as Australia, Southeast Asia and the Middle East.

Proceeds from the IPO will be used for capacity expansion, R&D, debt repayment and working capital, indicating a focus on scaling operations.

However, profitability metrics remain moderate, with return ratios and margins not yet fully reflecting the high valuation multiple, which likely weighed on investor appetite.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)

(You can now subscribe to our ETMarkets WhatsApp channel)

(What's moving Sensex and Nifty Track latest market news, stock tips, Budget 2025, Share Market on Budget 2025 and expert advice, on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .)

Subscribe to ET Prime and read the Economic Times ePaper Online.and Sensex Today.

Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price

...moreless

(You can now subscribe to our ETMarkets WhatsApp channel)

Subscribe to ET Prime and read the Economic Times ePaper Online.and Sensex Today.

Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price

...moreless

How a cozy club controls India’s gold imports

Trade was just the first casualty; RBI rate cuts may be next in the Iran War fallout

AI puts India’s USD190-billion services trade surplus at a crossroads

As IPO nears, NSE looks to settle long-running predatory pricing case

Beyond biscuits: ‘Forgotten brands’ power Britannia’s rise amid FMCG fall